Form 4 for SNWV SANUWAVE Health, Inc.
Accepted 2025-03-04 00:00:00 ET · period of report 2022-08-05 · accession 0001437749-25-006104 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-03-04 | 2024-10-18 | SNWV | Tyler James | Dir | A - Grant | — | +5,250 | 8,700 | +152% | — |
| D | 2025-03-04 | 2023-08-05 | SNWV | Tyler James | Dir | C - Cnv Deriv | $15.00 | +3,450 | 3,450 | New | +$51.8K |
| DM | 2025-03-04 | 2024-10-18 | SNWV | Tyler James | Dir | D - Sale to Iss | — | -4,559 | 3,000 | -60% | — |
| DM | 2025-03-04 | 2022-08-05+ | SNWV | Tyler James | Dir | A - Grant | $45,000.00 | +47.3K | 1,559 | New | +$2.13B |
| D | 2025-03-04 | 2023-08-05 | SNWV | Tyler James | Dir | C - Cnv Deriv | $0.00 | -3,000 | 3,000 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-18 | A | A | 2,700 | — | 6,150 | D | — | — | (F2) On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's warrants were exchanged for an aggregate of 5,250 shares of common stock pursuant to a letter agreement between the reporting person and the Company. |
| 2 | Common | Common Stock | 2023-08-05 | C | A | 3,450 | $15.00 | 3,450 | D | — | — | (F1) Pursuant to the terms of the Future Advance Convertible Promissory Note issued by SANUWAVE Health, Inc. (the "Company") on August 5, 2022, all principal and accrued interest due as of the maturity date, August 5, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share. |
| 3 | Common | Common Stock | 2024-10-18 | A | A | 2,550 | — | 8,700 | D | — | — | (F2) On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's warrants were exchanged for an aggregate of 5,250 shares of common stock pursuant to a letter agreement between the reporting person and the Company. |
| 4 | Derivative | Common Stock Purchase Warrant (right to buy) | 2024-10-18 | D | D | 1,559 | — | 41,333 | D | $25.13 · 2022-08-05 to 2027-08-05 | 3,000 Common Stock | (F2) On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's warrants were exchanged for an aggregate of 5,250 shares of common stock pursuant to a letter agreement between the reporting person and the Company. |
| 5 | Derivative | Common Stock Purchase Warrant (right to buy) | 2022-08-05 | A | A | 41,333 | — | 0 | D | $25.13 · 2022-08-05 to 2027-08-05 | 3,000 Common Stock | (F3) On August 5, 2022, in exchange for $45,000 in cash, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $45,000 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 3,000 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 3,000 shares of common stock at an exercise price of approximately $25.13 per share). |
| 6 | Derivative | Common Stock Purchase Warrant (right to buy) | 2024-10-18 | D | D | 3,000 | — | 3,000 | D | $15.00 · 2022-08-05 to 2027-08-05 | 3,000 Common Stock | (F2) On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's warrants were exchanged for an aggregate of 5,250 shares of common stock pursuant to a letter agreement between the reporting person and the Company. |
| 7 | Derivative | Common Stock Purchase Warrant (right to buy) | 2022-08-05 | A | A | 3,000 | — | 0 | D | $15.00 · 2022-08-05 to 2027-08-05 | 3,000 Common Stock | (F3) On August 5, 2022, in exchange for $45,000 in cash, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $45,000 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 3,000 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 3,000 shares of common stock at an exercise price of approximately $25.13 per share). |
| 8 | Derivative | Future Advance Convertible Promissory Note | 2023-08-05 | C | D | 3,000 | $0.00 | 3,000 | D | $15.00 · 2022-08-05 to 2023-08-05 | 3,450 Common Stock | (F2) On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's warrants were exchanged for an aggregate of 5,250 shares of common stock pursuant to a letter agreement between the reporting person and the Company. |
| 9 | Derivative | Future Advance Convertible Promissory Note | 2022-08-05 | A | A | 3,000 | $45,000.00 | 0 | D | $15.00 · 2022-08-05 to 2023-08-05 | 3,000 Common Stock | |
| 10 | Derivative | Stock Option (right to buy) | 2024-10-22 | A | A | — | $0.00 | 1,559 | D | $14.20 · — to 2034-10-22 | 41,333 Common Stock | (F4) Options will vest over a period of three years in 12 equal installments on each quarterly anniversary of the grant date. |
| 11 | Derivative | Stock Option (right to buy) | 2024-12-31 | A | A | — | $0.00 | — | D | $22.76 · — to 2029-12-31 | 1,559 Common Stock | (F5) Options were fully vested at the grant date. |